Thermo Fisher Scientific and NanoPin Technologies have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.
Through the detection of disease-related antigens directly from blood samples, NanoPin’s diagnostic platform using Thermo Fisher’s advanced LC-MS technology will lead to the development of sensitive clinical assays for infectious disease. This will enable healthcare providers to reduce time to results, determine infection stage, and monitor patient response to prescribed treatment. The information gleaned from the combined technology will support clinical decision-making and the provision of personalised patient care.
"Time is critical when it comes to the diagnosis and treatment of patients suffering from infectious disease, and current methods do not facilitate prompt diagnosis and rapid evaluation of treatment response," said Bradley Hart (Thermo Fisher Scientific).
Dr Thomas Tombler (NanoPin Technologies) said, "The current diagnostic solutions available for the detection and monitoring of infectious disease are not sufficient because they limit patient outcomes and the global management of such ailments. Through our agreement with Thermo Fisher, our diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated and controlled by solving the unmet needs of healthcare providers managing patient care throughout the world."